dr. sharma 1
TRANSCRIPT
Niraj Sharma, MD• Electrophysiologist at
CardioVascular Group/Gwinnett Medical Group
• Board Certified in Internal
Medicine, CardiovascularDiseases, and Electrophysiology
• Special interests include treating patients with abnormal heart rhythms, and ablation of arrhythmias, including atrial fibrillation.
Medical School:Medical College Jabalpur
Residency: Brown University
Fellowship: Univ. of Texas
Southwestern Medical Center
Niraj Sharma MD FACC FHRS
Gwinnett Health system
Atrial Fibrillation introduction and a little bit beyond…
You see a patient in the hospital and determine she needs warfarin. She does not want to take “rat poison” and asks you how effective it is.You quote warfarin efficacy (based on meta-trial data) as:A. 65% effective in ischemic stroke reductionB. 80% effectiveC. 90%D. 55%
Question # 0
A) 65%
Answer # 0
45 year old female hiker with symptomatic (palpitation) pAF has episodes lasting 3 days at a time. She has no other medical history. Based on the CHADSVASC score you will:A. AC with warfarinB. AC with Novel ACC. No ACD. Aspirin
Question # 1
C) No AC # 3
CHADSVASC score of 0 (female by itself is 0)
Answer # 1
CHADSVASC vs CHADS
60 year old male with asymptomatic permanent AF, with diabetes. Based on CHADSVASC score you would:A. AC with either Warfarin or NOACB. AspirinC. No ACD. Any of the above
Question # 2
D) current guidelines (CHADSVASC 1, if female than 2)….USA (AC in Europe)
More recent evidence suggests # 1 (AC) per Lip or #3 as per Friberg
Answer # 2
Relationship of stroke risk and AF duration is:A. Linear progressionB. Sigmoidal riskC. Log-rhythmicD. Stroke risk not assessed by duration
Question # 3
D) No relation
Assessment of stroke risk does not take into account duration
This is different if DCCV being planned
Answer # 3
78 year old male with DM, HTN, prior CVA presents to the ER at 11pm with new onset AF (started at 9pm while watching dancing with the stars) with RVR and has exertional SOB. Exam apart from AF, is unremarkable. You would:A. DCCV: because AF is <48 hours and the pt is
symptomaticB. TEE and then DCCVC. Rate control first, start AC and DCCV in 3-4
weeks D. Call Cardiology
Question # 4
C) Rate control first, start AC and DCCV in 3-4 weeks
CHADSVASC score does not have a role in evaluation stroke risk in patients undergoing DCCV
Caution while assessing 48 hour windowSymptomatic AF tip of iceberg
Answer # 4
76 year old female with confirmed “mildly” symptomatic AF and CHADSVASC score of 5 (female, HTN, DM, age) presents to your office. She is currently in AF and her vitals are: BP 148/88 P: irreg 90/min, other exam is unremarkable. The best option is:A. Start AC and initiate AAD treatment to reduce
episodes of AF and keep her in SRB. Start AC C. Start AC and get 24 hr Holter for VR controlD. AC for 3 weeks and DCCV and reassess
symptoms
Question # 5
D) AC for 3 weeks and DCCV and reassess symptoms
AFFIRM
Answer # 5
Dabigatran should NOT be used with which AAD?A. DronedaroneB. FlecanideC. SotalolD. DofetalideE. 1 and 4F. 1, 3 and 4G. 2 and 4
Question # 6
?Combination CI in EuropeCombination of Dabigatran and Dronedarone
increased blood levels of Dabigatran and increases risk of bleeding
Answer # 6
84 year old male with long standing persistent AF, DM, HTN, CABG, MV repair and ESRD on HD.The choice of AC is:A. ApixabanB. RivaroxabanC. WarfarinD. Dabigatran
Question # 7
C) Warfarin
MV repair= Valvular AF
Answer # 7
28 year old male with AF and incidental diagnosis of hypertrophic CMP on Echo done at PCP’s office for a murmur. He is referred to you for risk assessment. You would recommend:A. No AC CHADSVASC score of 0B. WarfarinC. ApixabanD. ASAE. B or C
Question # 8
E) B or C
HOCM is = CHADSVASC of 2Not considered “Valvular” AF
Answer # 8
Most common sustained rhythm problemMajor disease with 2.6million people in 2010
and projected be 12.5million in 2050Mortality rate with AF as primary or
secondary diagnosis increasing over the last 2 decades
Morbidity a major concern: 15-20% of ischemic strokes
Major economic burden to the patient as well as Healthcare
Why are we talking about “just” one disease?
Most common sustained rhythm problemMajor disease with 2.6million people in 2010
and projected be 12.5million in 2050Mortality rate with AF as primary or
secondary diagnosis increasing over the last 2 decades
Morbidity a major concern: 15-20% of ischemic strokes
Major economic burden to the patient as well as Healthcare
Why are we talking about “just” one disease?
EPIDEMIOLOGY
• The most prevalent sustained rhythm disorder
• Accounts for 1/3 of hospitalisations due to cardiac rhythm disturbances
• Estimated prevalence in USA 2.6 and worldwide 5.5 million
Arrhythmia-related hospitalisations
in the US
Atrial flutter 4% Paroxysmal
supraventriculartachycardia 6%
Atrial fibrillation
34%
Ventricular fibrillation
2%
Ventriculartachycardia
10% Miscellaneous 21%
Conductionabnormalities 8%
Sick sinussyndrome 9%
Prematurebeats 6%
AFib is responsible for a 5-fold increase in the risk of ischemic stroke
AFib is Responsible for 15-20% of all Strokes
Wolf PA, et al. Stroke (1991) 22: 983Go AS, et al. JAMA (2001) 285: 2370Friberg J, et al. Am J Cardiol (2004) 94: 889
12
02
8
4
41 53 2 41 53
Cu
mu
lati
ve s
troke in
cid
en
ce (
%)
Women AFib+
Women AFib-
Men AFib+
Men AFib-
Years of follow-up
Men 1.5x more then womenLess common in AA12% 75-84: 1% <60yrsTall (increase atrial size)/Obese (DM,OSA,
HTN, Systolic as well as diastolic dysfunction)Genetic rareAthletic lifestyle (high vagal tone)Cigarette smoking/Alcohol abuse
Epidemiologic data
Medicare Data
Classification
1. Paroxysmal AF- episode that spontaneously terminates in 7 days (~40% terminate in 24 hours)- minimal atrial scar most amenable to ablation i.e. stops by itself
2. Persistent AF- episode that lasts >7 days or requires cardioversion i.e. requires intervention
3. Permanent AF- fails to terminate with cardioversion or terminates and relapses within 24 hours- most amount of atrial scar least amenable to AAD or ablation i.e. end stage
ACC/AHA/HRS
ACC/AHA/HRS: Rheumatic MV disease, prosthetic valve or repair
ACCP: MS, prosthetic valveESC: Rheumatic valve disease, prosthetic
valveTrial definitions:
Valvular vs. non-valvular AFGuidelines
Valvular AF and trials
New Clasification
AF PathophysiologyCircRes.2014;114:1453-1468
CircRes.2014;114:1453-1468
Mechanism of AF
Knowing the risk of stoke is essentially similar in AF and in Atrial flutter, what would you prefer to have?A. AFB. Atrial flutter
Question # 9
B) Atrial flutter
Answer # 9
Mechanism of Atrial Flutter
Difference betweenFlutter and Fibrillation
1. Single large reentrant circuit in the RA
2. Difficult to rate control and usually not paroxysmal
3. Ablation first line of treatment
4. Ablation success >90-95%
5. Minimal risk for ablation6. AC can be stopped after
ablation if no associated AF
1. Multiple small foci in and around Pulmonary veins
2. Starts off as paroxysmal; easier to rate control
3. Ablation if AAD fail4. Ablation success 70-80%
for paroxysmal 60% for all
5. Can have serious complications
6. AC continued after ablation if risk factor ≥2
Ablation Line across the CTI
Treatment Options for AFib
Cardioversion
• Pharmacological
• Electrical
Drugs to prevent Afib (tomorrow)
• Antiarrhythmic drugs
Drugs to control ventricular rate (tomorrow)
Drugs to reduce thromboembolic risk (Dr Gangasani)
Non-pharmacological options
• Electrical devices (implantable pacemaker and defibrillator)
• AV node ablation and pacemaker implantation (ablate & pace)
• Catheter ablation/Hybrid ablation (Dr Harvey)
• Surgery (Maze, mini-Maze) (Dr Harvey)
• LAA closure devices: Lariat, Watchman (Dr Unterman)
When and Why Acutely Cardiovert?
AF Begets AF
AF causes changes in atrial electrophysiology that promote AF maintenance
Wijffels Circulation 1995; 92: 1954-68
In the ER you are consulted for new onset AF, started last night, with IV diltiazem controlled VR and now asymptomatic. The ER doc wants to DCCV and send home. AC is started. You would:A. Agree with herB. ED obs and DCCV in amC. TEE and DCCV in ER
Question # 10
# 2
Answer # 10
Likelihood of Spontaneous Conversion of Atrial Fibrillation to Sinus Rhythm
Danias J Am Coll Cardiol. 1998;31:588-92
• 356 pts with AF < 72 h• Symptoms of < 24 h was only independent predictor of
spontaneous conversion (OR: 1.8, p < 0.0001)
< 24 h
24 - 72 h
Total
292
64
356
73%
45%
68%
AF duration n Conversion
Cardioversion of atrial flutter and fibrillation after ibutilide infusion
Stambler Circulation. 1996;94:1613-1621
Predictors of Cardioversion with Ibutilide201 patients treated
Zaqqa AJC 2000
Oral NEJM 1999;340:1849-54
100 consecutive patients 50 assigned conventional
DC 50 pretreated with 1 mg
ibutilide
Card
iove
rsio
n s
ucc
ess
(%
)
Maintenance of Sinus Rhythm
Medicate or Ablate or Status quo
Treatment Options for AFib
Cardioversion
• Pharmacological
• Electrical
Drugs to prevent AFib
• Antiarrhythmic drugs
Drugs to control ventricular rate
Drugs to reduce thromboembolic risk
Non-pharmacological options
• AV node ablation and pacemaker implantation (ablate & pace)
• Catheter ablation/Hybrid ablation
• Surgery (Maze, mini-Maze)
Cardioversion
AFFIRMBaseline Characteristics
Age = 69.7 ± 9.0 yrs 39% female > 2 days of AF in 69% CHF class > II in 9% Symptomatic AF in 88%
Trials of Rate vs Rhythm Control
ACC/AHA/HRS Guidelines
Implications of Trials: Guideline Statement
Theoretically, rhythm control should have advantages over rate control, yet a trend toward lower mortality was observed in the rate-control arm of the AFFIRM study and did not differ in the other trials from the outcome with the rhythm control strategy. This might suggest that attempts to restore sinus rhythm with presently available antiarrhythmic drugs are obsolete. The RACE and AFFIRM trials did not address AF in younger, symptomatic patients with little underlying heart disease, in whom restoration of sinus rhythm by cardioversion antiarrhythmic drugs or non-pharmacological interventions still must be considered a useful therapeutic approach. One may conclude from these studies that rate control is a reasonable strategy in elderly patients with minimal symptoms related to AF. An effective method for maintaining sinus rhythm with fewer side effects would address a presently unmet need.
ACC/AHA/HRS Guidelines
Maze reproduction Schwarz 1994
Right atrial linear lesions Haïssaguerre 1994
Right and left atrial linear lesions Haïssaguerre 1996
PV foci ablation Jaïs / Haïssaguerre 1997/8
Ostial PV isolation Haïssaguerre 2000
Circumferential PV ablation Pappone 2000
Ablation of non-PV foci Lin 2003
Antral PV ablation Maroucche / Natale 2004
Double Lasso technique Ouyang / Kuck 2004
CFAE sites ablation Nademanee 2004
Ostial or circumferential or antral PV ablation plus extra lines (mitral isthmus, posterior wall, roof)
Jaïs / Hocini 2004/5
Circumferential PV ablation with vagal denervation
Pappone 2004
Technique Publication date
Landmarks in Catheter Ablation Techniques
Linear 443 75% 26% 33% 55%
Focal 508 81% 35% 54% 71%
Isolation 2,187 83% 36% 62% 75%
Circumferential (all) 15,455 68% 37% 64% 74%
Circumferential (LACA, WACA) 2,449 65% 37% 59% 72%
Circumferential (PVAI) 11,132 68% 42% 67% 76%
Substrate ablation (CFAE) 559 51% 49% 75% 87%
TOTAL 23,626 61% 55% 63% 75%
PatientsParoxysma
l AF 6-month cure 6-months OKAblation method SHD
Fisher JD, et al. PACE (2006) 29: 523
Meta-analysis of Catheter Ablation
Cure (by each author’s criteria) means no further AFib 6 months after the procedure in the absence of AAD.OK means improvement (fewer episodes, no episodes with previously ineffective AAD).SHD indicates structural heart disease.
Total success rate: 76%Of 8745 patients:
27.3% required 1 procedure52.0% asymptomatic without drugs23.9% asymptomatic with an AAD within <1
yr
Outcome may vary between centres
Worldwide Survey on Efficacy and Safety of Catheter Ablation for AFib
Cappato R, et al. Circulation (2005) 111: 1100
RF ablation vs AAD as first-line treatment for AFib
• Wazni OM et al. JAMA (2005) 293: 2634-2640
Catheter ablation in drug-refractory AFib• Stabile G et al. Eur Heart J (2006) 27: 216-221
Circumferential PV ablation for chronic AFib• Oral H et al. N Engl J Med (2006) 354: 934-941
Randomised Clinical Trials of Catheter
Ablation
Randomized Controlled Trial of Amiodarone + Cardioversion + Catheter Ablation
Oral H, et al. N Engl J Med (2006) 354: 9
Sin
us r
hyth
m (
%)
120
20
60
100
80
40
Months
1110987654321
Circumferentialpulmonary-vein ablationControl
Amiodarone & cardioversion (n=69) vs. amiodarone & cardioversion plus PV ablation (n=77)
Transient ischaemic attack 4 0.4 0 - 3
Permanent stroke 1 0.1 0 - 1
Severe PV stenosis(>70%, symptomatic) 3 0.3 0 - 3
Moderate PV stenosis(40-70%, asymptomatic) 13 1.3 0 - 5
Tamponade / perforation 5 0.5 0 - 3
Severe vascular access complication 3 0.3 0 - 4
Events(n)
Range in studies(%)
Rate(%)Complication
Complications Reported by Leading Centres
Major complications with pulmonary vein ablationin 1039 patients (6 series)
Verma A & Natale A Circulation (2005) 112: 1214
118 patients with symptomatic,drug-refractory AFib
32 weeks
1.52 ± 0.71 ablation procedures
Catheter ablationPharmacological treatment
Catheter Ablation May Be More Cost-effective than Pharmacological Therapy
Weerasooriya R, et al. Pacing Clin Electrophysiol (2003) 26: 292
€4715 followed by €445/year€1590/year
After 5 years, the cost of RF ablation was below that of medical management and further diverged thereafter
Clinical visits per year 7.4 (2.5) 1.1 (0.6)
Emergency room visits per year 1.7 (0.9) 0.03 (0.17)
Hospitalization days per year 1.6 (0.8) 0 (0)
Healthcare costs per year $1920 (889) $87 (68)
No ablation Catheter ablation
Differences in Hospital Visits and Costs with and without Catheter Ablation
Goldberg A, et al. J Interv Card Electrophysiol (2003) 8: 59
Although the initial cost of ablation is high, after ablation, utilization of healthcare resources is significantly reduced
Current ACC/AHA/ESC Guidelines
RecurrentParoxysmal AF
Minimal orno symptoms
Disabling symptomsin AF
Anticoagulation and rate control as needed
Anticoagulation and rate control as needed
No drug for preventionof AF AAD therapy
AF ablation if AADtreatment fails
ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation
Life style modification and AFLEGACY and ARREST-AF trials
LEGACY 2015
Methods
Results—AF freedom in different groups
Results
ARREST-AF 2014
ARREST-AF
Results
ARREST-AF